Literature DB >> 31499206

Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: A cluster randomized controlled trial.

Renate Richardus1, Khorshed Alam2, Kallyan Kundu2, Johan Chandra Roy2, Tasnuva Zafar2, Abu Sufian Chowdhury2, Daan Nieboer3, Roel Faber3, C Ruth Butlin2, Annemieke Geluk4, Jan Hendrik Richardus5.   

Abstract

OBJECTIVE: To assess the effectiveness of single-dose rifampicin (SDR) after bacillus Calmette-Guérin (BCG) vaccination in preventing leprosy in contacts.
METHODS: This was a single-centre, cluster-randomized controlled trial at a leprosy control programme in northwest Bangladesh. Participants were the 14988 contacts of 1552 new leprosy patients who were randomized into the SDR-arm (n=7379) and the SDR+arm (n=7609). In the intervention group, BCG vaccination was followed by SDR 8-12 weeks later. In the control group, BCG vaccination only was given. Follow-up was performed at 1year and 2 years after intake. The main outcome measure was the occurrence of leprosy.
RESULTS: The incidence rate per 10000 person-years at risk was 44 in the SDR-arm and 31 in the SDR+arm at 1year; the incidence rate was 34 in the SDR-arm and 41 in the SDR+arm at 2 years. There was a statistically non-significant (p=0.148; 42%) reduction for paucibacillary (PB) leprosy in the SDR+ arm at 1 year. Of all new cases, 33.6% appeared within 8-12 weeks after BCG vaccination.
CONCLUSIONS: In the first year, SDR after BCG vaccination reduced the incidence of PB leprosy among contacts by 42%. This was a statistically non-significant reduction due to the limited number of cases after SDR was administered. To what extent SDR suppresses excess leprosy cases after BCG vaccination is difficult to establish because many cases appeared before the SDR intervention. TRIAL REGISTRATION: Netherlands Trial Register: NTR3087.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bacillus Calmette–Guérin vaccine; Chemoprophylaxis; Household contacts; Immunoprophylaxis; Leprosy; Rifampicin

Mesh:

Substances:

Year:  2019        PMID: 31499206     DOI: 10.1016/j.ijid.2019.08.035

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

Review 1.  The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis.

Authors:  Anne Schoenmakers; Liesbeth Mieras; Teky Budiawan; Wim H van Brakel
Journal:  Res Rep Trop Med       Date:  2020-10-15

2.  Genomic Characterization of Mycobacterium leprae to Explore Transmission Patterns Identifies New Subtype in Bangladesh.

Authors:  Maria Tió-Coma; Charlotte Avanzi; Els M Verhard; Louise Pierneef; Anouk van Hooij; Andrej Benjak; Johan Chandra Roy; Marufa Khatun; Khorshed Alam; Paul Corstjens; Stewart T Cole; Jan Hendrik Richardus; Annemieke Geluk
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

3.  Leprosy stigma & the relevance of emergent therapeutic options.

Authors:  Kabir Sardana; Ananta Khurana
Journal:  Indian J Med Res       Date:  2020-01       Impact factor: 2.375

4.  Geospatial epidemiology of leprosy in northwest Bangladesh: a 20-year retrospective observational study.

Authors:  Caroline A Bulstra; David J Blok; Khorshed Alam; C Ruth Butlin; Johan Chandra Roy; Bob Bowers; Peter Nicholls; Sake J de Vlas; Jan Hendrik Richardus
Journal:  Infect Dis Poverty       Date:  2021-03-22       Impact factor: 4.520

Review 5.  Leprosy: A Review of Epidemiology, Clinical Diagnosis, and Management.

Authors:  Kou-Huang Chen; Cheng-Yao Lin; Shih-Bin Su; Kow-Tong Chen
Journal:  J Trop Med       Date:  2022-07-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.